Retatrutide | Triple Receptor Research Peptide

Description

Retatrutide is a novel triple receptor agonist that simultaneously targets the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple mechanism of action represents the cutting edge of metabolic research peptide pharmacology, and retatrutide has rapidly become one of the most important compounds for researchers investigating energy balance, adipose tissue biology, and cardiometabolic signalling.

Preclinical research into retatrutide and related triple receptor agonists has explored synergistic effects on insulin secretion, glucagon-mediated hepatic glucose output, energy expenditure via glucagon receptor activation, and adipose tissue lipolysis. The addition of glucagon receptor agonism to the dual GIP/GLP-1 profile creates a compound that research models suggest may produce greater metabolic effects than either semaglutide or tirzepatide alone, particularly with respect to thermogenesis and hepatic lipid clearance.

Retatrutide has a molecular weight of approximately 4,731 Da and CAS number 2381089-83-2. Its structure reflects a 39-amino-acid backbone with Aib substitutions and a C20 fatty-diacid conjugation via a chemical linker — a structural feature of particular interest in extended half-life research. Peptryn’s retatrutide is produced to ≥99% purity verified by HPLC and mass spectrometry, with an independent US laboratory COA included with every order. Supplied as sterile lyophilized powder for reconstitution.

Storage: Store lyophilized at -20°C, protected from light and repeated freeze-thaw cycles. Prepare any reconstituted solution fresh as required by your protocol. See our reconstitution guide for concentration math and handling protocol.

For laboratory and in vitro research use only. Not intended for human consumption, self-administration, or veterinary use.